| Literature DB >> 32511516 |
Ivan T Lee1,2,3,4, Tsuguhisa Nakayama2,4, Chien-Ting Wu5,4, Yury Goltsev1,4, Sizun Jiang1, Phillip A Gall2, Chun-Kang Liao6, Liang-Chun Shih7,8,9, Christian M Schürch1, David R McIlwain1, Pauline Chu1, Nicole A Borchard2, David Zarabanda2, Sachi S Dholakia2, Angela Yang2, Dayoung Kim2, Tomoharu Kanie5, Chia-Der Lin7,8,10, Ming-Hsui Tsai7,8,10, Katie M Phillips2, Raymond Kim2, Jonathan B Overdevest2,11, Matthew A Tyler2,12, Carol H Yan2,13, Chih-Feng Lin6, Yi-Tsen Lin6, Da-Tian Bau8,9, Gregory J Tsay10,14, Zara M Patel2, Yung-An Tsou7,10, Chih-Jaan Tai7,10, Te-Huei Yeh6, Peter H Hwang2, Garry P Nolan1,15, Jayakar V Nayak2,15, Peter K Jackson5,15.
Abstract
We investigated the expression and subcellular localization of the SARS-CoV-2 receptor, angiotensin-converting enzyme 2 (ACE2), within the upper (nasal) and lower (pulmonary) respiratory tracts of healthy human donors. We detected ACE2 protein expression within the cilia organelle of ciliated airway epithelial cells, which likely represents the initial or early subcellular site of SARS-CoV-2 viral entry during respiratory transmission. We further determined whether ACE2 expression in the cilia of upper respiratory cells was influenced by patient demographics, clinical characteristics, co-morbidities, or medication use, and found no evidence that the use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARBs) increases ACE2 protein expression.Entities:
Year: 2020 PMID： 32511516 PMCID： PMC7273284 DOI： 10.1101/2020.05.08.20092866
Source DB: PubMed Journal: medRxiv